Article Text
Abstract
Treatment-resistant depression (TRD) holds centrality in many debates regarding psychiatric euthanasia. Among the strongest reasons cited by opponents of psychiatric euthanasia is the uncertainty behind the irremediability of psychiatric illnesses. According to this argument, conditions that cannot be considered irremediable imply that there are possible remedies that remain for the condition. If there are possible remedies that remain for the condition, then patients with that condition cannot be considered for access to euthanasia. I call this the irremediability requirement (IR). I argue that patients with TRD can, indeed, meet the operationalisation of irremediability in the IR. This is because the irremediability it asks for is not some global or absolute irremediability, but rather a present irremediability based on the current state of medical science. I show this by considering irremediability relating to (1) possible future treatments and (2) not trying presently available alternative treatments. I extend Schuklenk nd van de Vathorst’s argument from parity to terminal malignancies, to show that (1) is an unreasonable expectation for all cases of euthanasia. Taking (2) as a more serious opponent to psychiatric euthanasia, I show how the IR, based on how it is presently operationalised, can be realistically applied to cases of TRD. I do this by further developing Tully’s argument on broad-sense treatment resistance with the robust empirical data from the STAR*D trials. If my argument from Tully’s is valid, then we have reasons to, again, seek parity between the operationalisations of irremediability in terminal malignancies and TRD.
- ethics- medical
- euthanasia
- mental disorders
- philosophy
Data availability statement
No data are available.
Statistics from Altmetric.com
Data availability statement
No data are available.
Footnotes
Contributors MT is the sole author of this work with no additional contributors. MT is the guarantor.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Efficacy of repetitive transcranial magnetic stimulation in treatment-resistant depression: the evidence thus far
- Long term outcome of thermal anterior capsulotomy for chronic, treatment refractory depression
- Treatment-resistant major depressive disorder and assisted dying
- Esketamine for treatment-resistant depression
- Is the exclusion of psychiatric patients from access to physician-assisted suicide discriminatory?
- Treatment-resistant depression and physician-assisted death
- Connectivity guided theta burst transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation for treatment-resistant moderate to severe depression: study protocol for a randomised double-blind controlled trial (BRIGhTMIND)
- Drawing the line on physician-assisted death
- Electroencephalography in the diagnosis and management of treatment-resistant depression with comorbid epilepsy: a novel strategy
- Choosing death in depression: a commentary on ‘Treatment-resistant major depressive disorder and assisted dying’